SCHEMBL30450179

SCHEMBL30450179

Clc1ccccc1COc1cccc(-c2ccc3[nH]cnc3c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.48
F9 P00740 1/20 0.47
NPC1 O15118 1/20 0.46
NR4A2 P43354 1/20 0.46
RAB9A P51151 1/20 0.46
NR1H2 P55055 1/20 0.45
NR1H3 Q13133 1/20 0.45
OTUD7B Q6GQQ9 2/20 0.44
QPCTL Q9NXS2 2/20 0.43
PTP4A3 O75365 1/20 0.41
DUSP4 Q13115 1/20 0.41
PTP4A1 Q93096 1/20 0.41
QPCT Q16769 2/20 0.40
CASP6 P55212 1/20 0.40
IGF1R P08069 1/20 0.39
ALOX5AP P20292 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17137719 1.00 EGLN1 (0.48) EGLN1F9NPC1NR4A2RAB9A
SCHEMBL17137754 0.86 EGFR (0.49) F9NPC1RAB9AQPCTIGF1R
SCHEMBL30450030 0.82 EGLN1 (0.48) EGLN1F9NR4A2
SCHEMBL17137537 0.82 EGLN1 (0.48) EGLN1F9NR4A2
SCHEMBL17137741 0.81 EGLN1 (0.48) EGLN1F9NR4A2
SCHEMBL30450790 0.81 EGLN1 (0.48) EGLN1F9NR4A2
SCHEMBL17137751 0.76 MAOB (0.50) F9NR4A2QPCTLPRMT5
SCHEMBL2096521 0.75 MMP12 (0.55) QPCTLQPCTLMNA
SCHEMBL2096516 0.75 QPCT (0.42) QPCTLQPCTPRMT5WDR77
SCHEMBL22418755 0.73 QPCT (0.47) NPC1RAB9AQPCTLQPCTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2023-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 EGLN1 8/4885F9 4377/4885NPC1 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.